Accellix, a San Jose, CA and Jerusalem, Israel-based cell therapy QC company, raised $9.5M in Series D funding.
The round was led by bioMérieux, with participation from existing major investors, who have also agreed to convert their pre-existing convertible note in the amount of $8.5m. This brought the company’s total funding in this round to $18m. In conjunction with the funding, Michael Reynier, bioMérieux Vice President, Healthcare Industries Business Area, will join the Accellix board.
This latest round will be used to further expand the market reach of the Accellix system for Cell Therapy QC, enabling its customers access to the expertise, scale, resources, and technology needed to assess the quality of life saving immunotherapies.
Led by Nir Nimrodi, Chairman and CEO, Accellix is a biotechnology company dedicated to developing and commercializing a platform to enable its customers in the field of cell and gene therapy to meet their critical QC requirements as they advance life changing therapies benefiting patients worldwide.